S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
S&P 500   5,258.09 (+0.18%)
DOW   39,811.48 (+0.13%)
QQQ   444.20 (-0.14%)
AAPL   171.69 (-0.93%)
MSFT   420.48 (-0.23%)
META   487.66 (-1.26%)
GOOGL   150.98 (+0.07%)
AMZN   180.30 (+0.26%)
TSLA   176.34 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.50 (-3.64%)
AMD   180.28 (+0.38%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   174.91 (-2.89%)
DIS   122.44 (+1.21%)
AMC   3.65 (-15.90%)
PFE   27.87 (+0.32%)
PYPL   67.13 (+0.84%)
XOM   116.09 (+0.97%)
NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

$11.14
-0.31 (-2.71%)
(As of 02:45 PM ET)
Today's Range
$11.12
$11.51
50-Day Range
$8.33
$12.29
52-Week Range
$5.22
$12.50
Volume
543,893 shs
Average Volume
957,755 shs
Market Capitalization
$2.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.4% Downside
$11.10 Price Target
Short Interest
Healthy
4.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Cellebrite DI in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.13%
From $0.32 to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Business Services Sector

263rd out of 311 stocks

Prepackaged Software Industry

185th out of 198 stocks

CLBT stock logo

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Cellebrite Pathfinder helps investigators reach conclusions faster through automated data ingestion, normalization, consolidation, and visualization of a suspects' journey; CryptoCurrency Investigative Solutions, which analyze blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets and transactions; and OSINT Investigate solution used to search, resolve, and enrich identifiers in open sources. In addition, the company provides Cellebrite Guardian, a cloud-based digital investigative data and evidence management SaaS solution that allows users to manage, store, share, and review investigative data and evidence from intake to creation of a final report; and Commander solution that enables collaboration across investigation functions to reduce manual processes. It serves federal and state and local agencies, as well as enterprise companies and service providers. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. is a subsidiary of Sun Corporation.

CLBT Stock Price History

CLBT Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Cellebrite Files its 2023 Annual Report on Form 20-F
Cellebrite Files its 2023 Annual Report on Form 20-F
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
UPDATE – Cellebrite Announces 2024 Investor Day
Cellebrite Announces 2024 Investor Day
William Blair Keeps Their Hold Rating on Cellebrite DI (CLBT)
Cellebrite (CLBT) Benefitting from Increased Data Volume
Cellebrite Announces Fourth-Quarter 2023 Results
See More Headlines
Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBT
Employees
1,005
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-3.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,100,000.00
Pretax Margin
-23.24%

Debt

Sales & Book Value

Annual Sales
$325.11 million
Cash Flow
$0.26 per share
Book Value
$0.18 per share

Miscellaneous

Free Float
193,595,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
1.56
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Yossi Carmil (Age 56)
    Founder, CEO & Director
    Comp: $946k
  • Ms. Dana Gerner (Age 57)
    Chief Financial Officer
    Comp: $477k
  • Mr. Leeor Ben-Peretz (Age 48)
    Chief Strategy Officer
    Comp: $416k
  • Mr. Marque Teegardin (Age 58)
    President of Cellebrite Americas - Sales Management
    Comp: $868.71k
  • Mr. Thomas E. Hogan (Age 65)
    Executive Chairman
  • Mr. Arnon Zilberman
    Executive Vice President of Information Systems & Operations
  • Mr. Ronnen Armon (Age 61)
    Chief Products & Technologies Officer
  • Andrew Kramer
    Vice President of Investor Relations
  • Ms. Ayala Berler Shapira
    General Counsel
  • Ms. Lisa Cole (Age 50)
    Chief Marketing Officer

CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings
or view top-rated stocks.

What is Cellebrite DI's stock price target for 2024?

5 Wall Street research analysts have issued 1 year price targets for Cellebrite DI's stock. Their CLBT share price targets range from $9.00 to $13.50. On average, they predict the company's share price to reach $11.10 in the next year. This suggests that the stock has a possible downside of 0.4%.
View analysts price targets for CLBT
or view top-rated stocks among Wall Street analysts.

How have CLBT shares performed in 2024?

Cellebrite DI's stock was trading at $8.66 at the start of the year. Since then, CLBT stock has increased by 28.6% and is now trading at $11.14.
View the best growth stocks for 2024 here
.

Are investors shorting Cellebrite DI?

Cellebrite DI saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,620,000 shares, an increase of 11.5% from the February 29th total of 2,350,000 shares. Based on an average daily volume of 978,000 shares, the short-interest ratio is presently 2.7 days. Approximately 4.7% of the shares of the company are short sold.
View Cellebrite DI's Short Interest
.

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CLBT earnings forecast
.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) announced its quarterly earnings results on Thursday, February, 15th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The firm earned $93.01 million during the quarter, compared to analyst estimates of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive trailing twelve-month return on equity of 173.14%.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).

What guidance has Cellebrite DI issued on next quarter's earnings?

Cellebrite DI updated its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include IGP Investments G.P.L.P LP (11.18%), Clal Insurance Enterprises Holdings Ltd (3.76%), Crosslink Capital Inc. (1.72%), Greenhaven Road Investment Management L.P. (1.52%), Voss Capital LLC (0.97%) and Ashford Capital Management Inc. (0.79%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners